Risk of hip fracture after bisphosphonate discontinuation: Implications for a drug holiday

Osteoporosis International

Volumn 19, Issue 11, 2008, Pages 1613-1620

  Curtis, J R ^a   Westfall, A O ^a   Cheng, H ^a   Delzell, E ^a   Saag, K G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adherence; Bisphosphonates; Compliance; Discontinuation; Fracture

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIP FRACTURE; HUMAN; INCIDENCE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH SERVICES; HIP FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; UNITED STATES;

EID: 53549128356     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-008-0604-4     Document Type: Article

References (14)

1. DM Black AV Schwartz KE Ensrud 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 296 24 2927 2938
2. HG Bone D Hosking J-P Devogelaer 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women N Engl J Med 350 12 1189 1199
3. L Mortensen P Charles PJ Bekker J DiGennaro Jr 1998 JCC: Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up J Clin Endocrinol Metab 83 396 402
4. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 3 1294 1301
5. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 9 1453 1460
6. JR Curtis AO Westfall JJ Allison A Freeman KG Saag 2006 Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users Osteoporos Int 17 8 1268 1274
7. MA Brookhart J Avorn JN Katz 2007 Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance Am J Med 120 3 251 256
8. RA Yood S Emani JI Reed BE Lewis M Charpentier E Lydick 2003 Compliance with pharmacologic therapy for osteoporosis Osteoporos Int 14 12 965 968
9. ES Siris ST Harris CJ Rosen 2006 Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases Mayo Clin Proc 81 8 1013 1022
10. WA Ray MR Griffin RL Fought ML Adams 1992 Identification of fractures from computerized Medicare files J Clin Epidemiol 45 7 703 714
11. SL Silverman NB Watts PD Delmas JL Lange R Lindsay 2007 Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos Int 18 1 25 34
12. Curtis JR, Westfall AO, Allison JJ, Freeman A, Kovac SH, Saag KG (2006) Agreement and validity of pharmacy data and self-report for use of osteoporosis medications among chronic glucocorticoid users. Pharmacoepi Drug Safety 15(10):710-718
13. GH Nancollas R Tang RJ Phipps 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 5 617 627
14. Curtis JR, Mudano A, Solomon DH, Kim Y, Saag KG (2007) Identifying clinical vertebral fractures using administrative claims data: a validation study. J Bone Miner Res 22(1):S199